Is Guangxi Wuzhou Zhongheng Group planning to sell the controlling stake of Chongqing Lummy Pharmaceutical after years of consecutive losses? | Quick read announcement

①Guangxi Wuzhou Zhongheng Group intends to transfer the shares held directly in Chongqing Lummy Pharmaceutical through public solicitation, and the controlling shareholder and actual controller of the latter may change. ②The story of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019 and became a major shareholder of Chongqing Lummy Pharmaceutical in April of the following year, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical since then. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous loss-making state.

cls.cnNov 26 22:55

This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?

According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.

Securities TimesNov 26 19:39

Abnormal trading investigation! The big bull stock special treat Jingfeng has been suspended for the first time, with an increase of over 752% in more than four months | Quick read of the announcement.

①*ST Jingfeng suspended trading for the first time this year due to abnormal fluctuations; ② The cumulative deviation of the closing price for two consecutive trading days reached 15.39%; ③ The stock price has increased by 752.78% in the past four months; ④ There is still uncertainty about the highly anticipated pre-restructuring matters.

cls.cnNov 17 19:31

"Going global" and "innovation" are the key words that cannot be bypassed. Sun Piaoyang from Jiangsu Hengrui Pharmaceuticals, Zhu Yi from Baheal Pharm and other top pharmaceutical industry leaders jointly discuss the next decade | Industry Observation

① On November 14, 2024, the Qisi Conference opened in Chengdu, where experts in the pharmaceutical field, investors, and chairpersons of leading listed companies discussed the challenges and opportunities currently facing the china meheco group industry. ② The two key phrases "going overseas" and "innovation" ran throughout the meeting. ③ In response to the question of the future direction of innovative drugs in china, various companies provided different answers.

cls.cnNov 15 11:16

Foreign public fund latest hold positions exposure! Fund managers are bullish on china's stock market valuation repair.

With the disclosure of the third quarter report, public funds under international asset management giants such as BlackRock and Fidelity have all their holdings exposed.

Securities TimesOct 29 10:07

The hottest summer Ai Ye Zheng Qi is not selling well, chongqing taiji industry's Q3 performance has dropped by 70%|interpretations

In 2024, the national average temperature is the highest in the same period since 1961, but the sales volume of chongqing taiji industry Huoxiang Zhengqi Oral Liquid in the third quarter has significantly decreased, with a sharp drop in large single product sales, resulting in more than a 70% year-on-year decrease in chongqing taiji industry's third-quarter profit.

cls.cnOct 24 21:59